Payment overview · 2025
General Payments
$516.68
27 reported records · 8 companies
Healthcare provider profile · identity verified
Robert K Mccowan, DO
Allopathic & Osteopathic Physicians|Family Medicine · LENOX, MI · NPI 1053380402
Verified facts
What the public records show
CMS Open Payments records show Robert K Mccowan, DO received $516.68 in general payments during 2025 across 27 reported records.
Novo Nordisk Inc accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.54 | 31.6% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $101.61 | 19.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.22 | 13.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.75 | 12.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.50 | 11.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.47 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.38 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.21 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $516.68 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $101.61 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $94.60 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.94 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.75 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.50 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.50 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.10 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 113 |
| Lisinopril | Lisinopril | 298 | 83 |
| Metformin Hcl | Metformin Hcl | 259 | 89 |
| Losartan Potassium | Losartan Potassium | 230 | 77 |
| Simvastatin | Simvastatin | 218 | 73 |
| Alprazolam | Alprazolam | 208 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 60 |
| Omeprazole | Omeprazole | 199 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 54 |
| Gabapentin | Gabapentin | 166 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 56 |
| Sertraline Hcl | Sertraline Hcl | 155 | 49 |
| Furosemide | Furosemide | 146 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 20 |
| Allopurinol | Allopurinol | 85 | 26 |
| Ozempic | Semaglutide | 85 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 31 |
| Eliquis | Apixaban | 82 | 28 |
| Prednisone | Prednisone | 82 | 59 |
| Trazodone Hcl | Trazodone Hcl | 82 | 23 |
| Ezetimibe | Ezetimibe | 77 | 28 |
| Enalapril Maleate | Enalapril Maleate | 74 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 11 |
| Atenolol | Atenolol | 71 | 17 |
| Amoxicillin | Amoxicillin | 70 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 21 |
| Potassium Chloride | Potassium Chloride | 67 | 30 |
| Tramadol Hcl | Tramadol Hcl | 66 | 19 |
| Ibuprofen | Ibuprofen | 64 | 32 |
| Finasteride | Finasteride | 62 | 18 |
| Cephalexin | Cephalexin | 61 | 51 |
| Famotidine | Famotidine | 59 | 17 |
| Glipizide | Glipizide | 59 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 20 |
| Jardiance | Empagliflozin | 57 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 28 |
| Carvedilol | Carvedilol | 52 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 13 |
| Chlorthalidone | Chlorthalidone | 48 | 16 |
| Meloxicam | Meloxicam | 48 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 17 |
| Celecoxib | Celecoxib | 45 | 14 |
| Methylprednisolone | Methylprednisolone | 45 | 40 |
| Montelukast Sodium | Montelukast Sodium | 45 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 11 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Ramipril | Ramipril | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 12 |
| Glimepiride | Glimepiride | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Nystatin | Nystatin | 27 | 16 |
| Xarelto | Rivaroxaban | 27 | 11 |
| Baclofen | Baclofen | 26 | suppressed |
| Briviact | Brivaracetam | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | 11 |
| Ketoconazole | Ketoconazole | 23 | 12 |
| Spironolactone | Spironolactone | 23 | 11 |
| Hydrocortisone | Hydrocortisone | 22 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Lacosamide | Lacosamide | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 15 |
| Colchicine | Colchicine | 18 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 14 |
| Mupirocin | Mupirocin | 16 | 15 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | 11 |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $516.68 · 27 records | Novo Nordisk Inc | AIRSUPRA, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error